Navigation Links
Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Date:10/30/2013

CAMBRIDGE, Mass., Oct. 30, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

This study did not meet the primary endpoint of progression free survival in the overall population.  The hazard ratio (HR) for progression free survival (PFS) was 1.0 [95% CI 0.74 - 1.4].

Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel. When using a combination of two biomarkers, the hazard ratio for PFS was 0.37 [95% CI 0.2 - 0.8] in the 34% of patients who were biomarker positive. The hazard ratio for PFS in the biomarker negative population was 1.54 [95% CI 1.0 - 2.4].

An overall increase in all grades of gastrointestinal toxicities, including diarrhea (73.6% vs. 42.5%), vomiting (31.4% vs. 18.8%) and other mucosal toxicities such as rhinitis (7.1% vs. 1.3%), epistaxis (23.6% vs. 17.5%), stomatitis (22.1% vs. 10.0%) and mucosal inflammation (22.1% vs. 1.3%), were observed in the combination as compared to paclitaxel alone, the majority of which were mild to moderate in severity. An increase in the pulmonary embolism rate was observed with the combination of MM-121 and paclitaxel (5.0% vs. 1.2%). No enhancement of paclitaxel-related peripheral neuropathy was reported with the combination.

"This unique study design lays the groundwork for future translational studies in ovarian cancer. The rapid enrollment into this study was a testament to the commitment of patients and physicians to advance our knowledge and improve upon available therapies i
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
6. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
7. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
11. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.C. , July 24, 2014 ... has signed an Agreement with Kineticos, a ... consulting company. Kineticos will support LSI Medience in ... sepsis management, to demonstrate utility in clinical trials. ... shown potential utility in diagnosis of sepsis, prognosis ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... "North America Orthopedic Braces and Supports Market Outlook to ... Orthopedic Braces and Supports market. The report provides value, ... and average price data (in US dollars), within market ... , Ankle Braces and Supports , Spinal Braces ... Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
(Date:7/24/2014)... MEMPHIS, Tenn. Researchers at Le Bonheur Children,s Hospital ... results of a clinical trial of a new drug ... illness of healthy adult volunteers intranasally infected with respiratory ... of lower respiratory tract infections in young children in ... comes from the labs of Infectious Disease Specialist John ...
(Date:7/24/2014)... 24, 2014 In signing the ... Obama cited the Atlanta BeltLine Workforce Partnership in ... across the country ( http://www.whitehouse.gov/ready-to-work ). The ... pillar of U.S. economic strategy and profiled successful ... recognition from President Obama highlights the power of ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... E. Taylor, M.D., director of The Miriam Hospital,s ... 2014 Rhode Island Medical Journal special ... c virus infection (hep c or HCV) is ... address other health challenges, and improve health care ... States, Taylor says, include lack of funding earmarked ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... Children who can read and have good phonetic skills - ... may still be poor spellers. In a paper published in ... Annett, at the School of Psychology of Leicester, UK, show ... be right-handed than other poor spellers. , The three-year study ...
... May 29 Alsius Corporation,(Nasdaq: ALUS ... (IVTM(TM)) therapies for critically ill patients, was ... L.P. to provide,intravascular temperature management products to ... the fifth contract we have been awarded ...
... to what is known about relationship between fitness and,diabetes, ... 2 diabetes in women is significantly increased as a ... Index (BMI), and a,combination of the two increases the ... at the 55th Annual Meeting of the American,College of ...
... a first for URAC, the,independent, non-profit accreditation organization ... has developed to help case management,practitioners assess patient ... instrument is a standardized assessment case managers,can voluntarily ... from any interested,parties, including purchasers, policy makers, consumers, ...
... that they have coordinated all the entertainment for Rhinestone ... Hotel Indigo, on,West End, from 7pm until midnight., ... a,place for you to connect with artists, friends and ... the world of country music quick, easy,and free!, ...
... firefighters study to be presented at ... American College of Sports Medicine, MISSOULA, ... Exercise Metabolism (Montana WPEM) will present a human,clinical study at ... that wildland firefighters who consumed a yeast based,(beta glucan) antioxidant ...
Cached Medicine News:Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 2Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 4Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 2Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 3Health News:DigitalRodeo.com Lines Up Entertainment for Rhinestone Cure 2Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2
The AutoSet Respond offers ResMeds unique AutoSet algorithm and product quality in a convenient, affordable model. The AutoSet algorithm responds to the patients pressure needs on a breath-by-breath ...
... The AutoSet Spirit is the premium ... flow generators, S7. The AutoSet algorithm responds ... breath-by-breath basis. The flow generator stores and ... software. The AutoSet devices combine integrated ...
These products are primarily for use with paediatric patients and for patients with difficult veins....
... Blood Collection Sets allow you to ... safety. The BD Vacutainer® Safety-Lok™ Blood ... be shielded with one-handed activation. This ... and infusion procedures. It comes with ...
Medicine Products: